Said Joanne Graham find the answers.
A new PhysicianForum primary market research report entitled Oral Chemotherapeutic Agents: Key Success Factors and Reimbursement Issues was found that during the use of oral chemotherapy drugs is on the rise, some physicians point to reduced reimbursement rates for doctors as a factor the use of the use of traditional intravenous chemotherapy. – Oncologists and managed care pharmacy directors agree that oral chemotherapy agents assume a larger role, as more than 80 percent of the physicians we interviewed stated that they use of these funds between May 2003 and May 2005 increased, said Joanne Graham, analyst at Decision Resources, however, said only about 20 percent of pharmacy directors surveyed see an increase in co-payments for certain oral agents, including erlotinib and temozolomide. find the answers .
Based Oral chemotherapeutics Key Success Factors and reimbursement issues to a U.S. Study of 20 HMO pharmacy directors and 96 oncologists Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.
For more information on this AHRQ Messaging and figures see Trends in Employer – Sponsored Health Insurance Plans in that require not a corporate employee contribution to premium cost, 1998-2004.
The share of U.S. Private-sector employees enrolled an employer eighteen sponsored health plans which do not declined them the cost of their premium stock by one-third 1998 to 2,004 from 27 % to per cent in 2004, according to the latest Messaging and number of of the Agency for Healthcare research and Quality.